ML-016 in Advanced Cancer With Lung and/or Liver Involvement

ML-016 in Advanced Cancer With Lung and/or Liver Involvement is a phase 1/2, interventional study registered as NCT07723482 by BrYet US, Inc., with a registry enrolment figure of 108 participants, started 2026-08 and due to reach its primary completion in 2027-08. Interventions recorded: ML-016. Conditions listed: Advanced Solid Tumor With Lung and/or Liver Involvement. Primary outcome: Incidence of dose-limiting toxicities (DLTs) during the DLT assessment period; Frequency and severity of adverse events (AEs) and serious AEs (SAEs); Maximum tolerated dose (MTD) and doses recommended for expansion. Lung eligibility wording from the registry: "Evidence of tumor in the lung and/or liver based on imaging studies". Sites: Australia. No results are recorded here; the registry entry is the source.